# Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma

> **NCT03994627** · — · APPROVED_FOR_MARKETING · sponsor: **Eli Lilly and Company**

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Olaratumab

## Key facts

- **NCT ID:** NCT03994627
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03994627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03994627, "Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03994627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*